Twenty‐year time trends in use of evidence‐based heart failure drug therapy in Denmark. Issue 1 (14th February 2020)

• Record Type: Journal Article
• Authors: Vinter, Nicklas; Jensen, Martin; Skjøth, Flemming; Larsen, Torben Bjerregaard; Frost, Lars; Johnsen, Søren Paaske
• Is Part Of: Basic & clinical pharmacology & toxicology. Volume 127:Issue 1(2020)
• Page Start: 30
• Page End: 38
• Publication Date: 2020-02-14
• Subjects: dosage -- drug utilisation -- guidelines -- heart failure -- trends; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology, Clinical -- Periodicals; Computer network resources; Electronic journals; 615.1
• DOI: 10.1111/bcpt.13392
• Languages: English
• ISSNs: 1742-7835

Abstract

Abstract: European guidelines for heart failure (HF) have continuously incorporated new evidence since the first publication in 1995. We aimed to explore time trends in utilisation of pharmacological treatment for HF and dispensing of recommended dosages among patients with a first‐time diagnosis of HF. We performed a historical cohort study of patients with a first‐time HF diagnosis from 1997 to 2015, identified in the Danish National Patient Registry. Dispensed pharmacological treatment included angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta‐blockers, mineralocorticoid receptor blockers (MRAs), digoxin and diuretics. Furthermore, we estimated the proportion of patients receiving the recommended target dosages 1 year after the diagnosis. The utilisation increased and correlated with publication of landmark studies, and among patients diagnosed in 2015, approximately two of three received ACEI/ARB and beta‐blocker, respectively. Less than half of the patients redeeming prescriptions for ACEIs, ARBs, beta‐blockers or MRAs received the recommended target dosages. The utilisation of pharmacological therapy for HF appears to be correlated with the publications of landmark Phase III clinical trials. However, a high proportion of patients do not receive the recommended target dosages. Despite improvements over time, a substantial gap appears to remain between guideline recommendations and pharmacological therapy in routine care.